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Abstract
Glaucoma is a disease frequently associated with elevated intraocular pressure that can be alleviated by filtration surgery.
However, the post-operative subconjunctival scarring response which blocks filtration efficiency is a major hurdle to the
achievement of long-term surgical success. Current application of anti-proliferatives to modulate the scarring response is
not ideal as these often give rise to sight-threatening complications. SPARC (secreted protein, acidic and rich in cysteine) is a
matricellular protein involved in extracellular matrix (ECM) production and organization. In this study, we investigated post-
operative surgical wound survival in an experimental glaucoma filtration model in SPARC-null mice. Loss of SPARC resulted
in a marked (87.5%) surgical wound survival rate compared to 0% in wild-type (WT) counterparts. The larger SPARC-null
wounds implied that aqueous filtration through the subconjunctival space was more efficient in comparison to WT wounds.
The pronounced increase in both surgical survival and filtration efficiency was associated with a less collagenous ECM,
smaller collagen fibril diameter, and a loosely-organized subconjunctival matrix in the SPARC-null wounds. In contrast, WT
wounds exhibited a densely packed collagenous ECM with no evidence of filtration capacity. Immunolocalization assays
confirmed the accumulation of ECM proteins in the WT but not in the SPARC-null wounds. The observations in vivo were
corroborated by complementary data performed on WT and SPARC-null conjunctival fibroblasts in vitro. These findings
indicate that depletion of SPARC bestows an inherent change in post-operative ECM remodeling to favor wound
maintenance. The evidence presented in this report is strongly supportive for the targeting of SPARC to increase the success
of glaucoma filtration surgery.
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Introduction
Glaucoma is the most common cause of irreversible blindness
worldwide. The World Health Organisation (WHO) estimates the
number of people blinded from glaucoma in 2002 was 4.4 million
[1]. The number of people affected worldwide with glaucoma is
predicted to be 79.6 million by 2020, of which over 8 million will
suffer from bilateral blindness [2]. Elevated intraocular pressure
(IOP) is the most important modifiable risk factor for the
development and progression of glaucomatous optic neuropathy,
which can lead to blindness [3]. Surgery in the form of filtration
surgery is considered the most effective method of achieving a
consistently desirable low IOP when topical medications are
ineffective. This surgery involves the formation of a fistula to
maintain blood and aqueous humour flow. A major complication
of this surgery, leading to an increased risk of surgical failure and
morbidity, is the post-operative wound healing response via
obstruction of the fistula by excessive extracellular matrix (ECM)
deposition [4]. To limit the post-operative scarring response,
physicians often employ anti-proliferative agents to improve
surgical outcomes. Mitomycin C (MMC) and 5-fluorouracil
(5 FU) are currently used to improve surgical outcomes in
glaucoma filtration surgery [5–7]. Despite their use intraopera-
tively as well as postoperatively, a significant failure rate persists
and is associated with sight-threatening infections [8,9]. Therefore,
the quest to find an alternative, safe, effective, and targeted anti-
fibrotic is ongoing.
SPARC (secreted protein, acidic and rich in cysteine), also
known as osteonectin and BM-40, is a 32 kDa calcium-binding
matricellular protein that modulates cell-extracellular matrix
(ECM) interactions without contributing structurally to the ECM
[10,11]. There is a strong association between elevated expression
of SPARC and tissue scarring and fibrosis. Increased expression of
SPARC has been observed in fibrotic disorders of the skin [12,13],
lungs [14], kidneys [15,16], liver [17], and atherosclerotic lesions
[18]. Conversely, the SPARC-null (SPARC2/2) mouse exhibited
diminished bleomycin-induced pulmonary fibrosis [19] in addition
to other characteristics indicative of a compromised maturation
and assembly of the ECM. These reports strongly implicate
SPARC as a protein involved in tissue remodeling and repair via
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SPARC to reduce not only fibrosis but, more importantly, to
preserve wound function that is surgically induced to alleviate a
disease condition, has not been described.
In the present study, we show in vitro that SPARC2/2
conjunctival fibroblasts do not respond to TGF-b2 via increased
expression of ECM proteins. Moreover, SPARC2/2 cells display
lower MMP-2 activity that corresponds to a reduction in the rate of
collagen gel contraction. We further demonstrate in vivo, by the use
of a murine model of glaucoma filtration surgery, that SPARC
deficiency can maintain the surgically-induced wound for a longer
period of time compared to WT. Specifically, at 14 days post-
surgery, 87.5% of the operated SPARC2/2 mice retained the
blebs compared to 0% of the operated WT mice. We conclude that
thisobservedphenomenonisduetoan altered ECMcompositionin
the SPARC2/2 wounds which contained less collagen I relative to
the WT counterparts. We have therefore provided evidence for the
first time of a novel role for SPARC depletion as a promising
effective therapeutic method for preservation of wound filtering
function in glaucoma filtration surgery.
Materials and Methods
Cell Culture
SPARC-null (SPARC2/2) mice and their corresponding WT
counterparts (C57Bl6/J) have been described previously [20].
Conjunctival fibroblasts obtained from WT and SPARC2/2 mice
were cultured as explants in culture medium consisting of Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum and Penicillin G-streptomycin sulfate (100 U/ml and
100 mg/ml, respectively) at 37uC in a humidified incubator
containing 5% CO2. Fibroblasts that migrated out from the tissue
were propagated in the same medium. To induce a fibrotic response,
we stimulated cells with 2 ng/ml recombinant TGF-b2( P e p r o T e c h
Inc., NJ, USA) for 72 h prior to real-time polymerase chain reaction
(PCR) assay. All tissue culture reagents were obtained from
Invitrogen Corp. (CA, USA) unless otherwise stated.
RNA Isolation and Expression
Total RNA was recovered with Trizol Reagent (Invitrogen
Corp.) according to the manufacturer’s recommendations. First-
strand cDNA was synthesized with 500 ng total RNA extract and
1 ml of 50 ng/ml random hexamer primer (Invitrogen Corp.) with
Superscript III reverse transcriptase (Invitrogen Corp.) according
to the manufacturer’s instructions. Quantitative real-time PCR
(qPCR) was performed in a total volume of 10 ml in 384-well
microtiter plates. Each reaction consisted of 1 ml of first-strand
reaction product, 0.5 ml each of upstream and downstream
primers (10 mM each), 4 ml of Power SYBR Green PCR Master
Mix (Applied BioSystems, CA, USA), and 4 ul of DNase-RNase-
free distilled water (Sigma-Aldrich Corp., MO, USA). Amplifica-
tion and analysis of cDNA fragments were carried out by use of
the Roche LightCycler 480 System (Roche Diagnostics Corp,
Indianapolis, USA). All PCR reactions were performed in
triplicate. All mRNA levels were measured as CT threshold levels
and were normalized with the corresponding b-actin CT values.
Values are expressed as fold increase over the corresponding
values for untreated WT control by the 2
2DDCT method. The
primers used are shown in Table S1.
Collagen Gel Cultures
Cultured mouse fibroblasts were detached by treatment with
trypsin, washed twice with DMEM, and resuspended in FBS at a
density of 1.35610
6 per ml. Type I collagen (5 mg/ml, Sigma-
Aldrich), 10x DMEM, and cell suspension were mixed on ice in a
volume ratio of 6:2.5:1.5 (final concentration of type I collagen,
3 mg/ml; final cell density, 2610
5 per ml). 0.25 ml of the collagen
gel suspension was added to each well of a 24-well cell culture dish,
and polymerization was induced by incubation at 37uC for 30
minutes. Gels were detached and the wells were topped up with
0.5 ml of culture medium. Quantification of contraction at day-1,
-3 and -5 was performed with the Kodak Image Station 4000R
(Carestream Molecular Imaging, New Haven, USA). All exper-
iments were performed in triplicate.
Zymography and Western Blot Analysis
To determine MMP-2 activity, we resolved equal protein
concentrations of conditioned medium recovered from contracted
collagen gels on day-5 on pre-cast 10% SDS-polyacrylamide slab
gels containing 0.1% gelatin (Invitrogen Corp.). After electropho-
resis, gels were renatured in renaturing buffer (Invitrogen Corp.)
for an hour and then incubated with developing buffer (Invitrogen
Corp.) overnight for maximum sensitivity. MMP activity was
visualized by staining the gels with Simplyblue Safestain (Invitro-
gen Corp.) for 1 hour. Images were taken and analysed with the
Kodak Image Station 4000R (Carestream Molecular Imaging.,
New Haven, USA). Densitometric quantitation was performed
using the Kodak Image Station 4000R (Carestream Molecular
Imaging, New Haven, USA).
For recovery of fibroblasts from the gels, gels were treated as
described in a previous report [21]. The dispersed cells were lysed
with extraction buffer (20 mM Tris-buffer, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 0.5% (volume/volume) Triton X-100,
2 mM MgCl2,
1 mM dithiothreitol), and protein content was assessed by the
Coomassie Plus Protein Assay Reagent (Thermo Fisher Scientific
Inc., IL, USA). Equal amounts of protein were separated by
electrophoresis on a 10% SDS gel, transferred to nitrocellulose
filters, and probed with a rabbit antibody against MT1-MMP
(Abcam plc, Cambridge, UK) followed by a horseradish-
peroxidase-conjugated second antibody. Subsequently the blots
were developed with SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo Fisher Scientific Inc., IL, USA).
Blots were stripped and probed with a rabbit antibody against
GAPDH (Santa Cruz Biotechnology, Inc., CA, USA). Densito-
metric quantitation was performed as previously outlined and
results were corrected to GAPDH levels, used as a housekeeper, to
correct for potential errors in loading.
Mouse Model of Glaucoma Filtration Surgery
C57Bl/6J WT and SPARC2/2 mice were bred and
maintained at the Department of Experimental Surgery (Singa-
pore General Hospital, Singapore). All experiments with animals
were approved by the Institutional Animal Care and Use
Committee (IACUC). The modified filtering surgery in the mouse
eye was performed as described in the text. The wound was
secured and closed at the limbus by a 10-0 (0.2 metric) Ethilon
black monofilament nylon scleral suture (Ethicon, Inc.). Fucithal-
mic ointment (Leo Pharmaceutical Products, Ballerup, Denmark)
was instilled at the end of the procedure. Surgery was performed
on eight WT and eight SPARC2/2 eyes.
Detection and Measurement of Blebs
Careful slit lamp and anterior segment-optical coherence
tomography (AS-OCT) examinations on subconjunctival blebs
were performed daily until post-operative day 3, after which the
blebs were observed every 3 to 4 days until postoperative day 14.
Slit lamp biomicroscopy was performed with the Nikon FS-3V
SPARC Alters Surgical Fibrosis
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eyes of each genotype were measured by OCT with the Visante
TM
OCT, Anterior Segment Imaging Model 1000 (Carl Zeiss
Meditech Inc., Dublin, CA, USA), and the images were analysed
with the Visante
TM OCT software. In vivo confocal microscopy
using the Heidelberg retina tomography HRT3 (Heidelberg
Engineering GmbH, Germany) was performed for three eyes of
either genotype. In vivo confocal images were analysed with the
Heidelberg Eye Explorer version 1.5.1 software (Heidelberg
Engineering GmbH, Germany).
Histology and Immunofluorescent Analyses
Control un-operated or operated eyes recovered on day-14
post-surgery were fixed in 4% paraformaldehyde before processing
and sectioning with the Microm HM550 (Carl Zeiss Ltd). 5 mm
sections were stained with hematoxylin and eosin to visualize tissue
morphology. To assess the collagen matrix, we performed
picrosirius red staining and visualized the sections by polarization
microscopy (Olympus BX51, Olympus, USA) as previously
described [22]. For immunofluorescent analysis, we used antibod-
ies specific for SPARC (Santa Cruz Biotechnology, Inc., CA,
USA), collagen (Abcam plc, Cambridge, UK), fibronectin (Abcam
plc, Cambridge, UK), and MMP-2 (Abbiotec, LLC, CA, USA).
Secondary antibodies were conjugated to either AlexaFluro-488 or
AlexaFluro-594 (Invitrogen). Sections were visualized under the
FV1000 confocal microscope (Olympus, USA). Histological and
immunofluorescent analyses were performed on three sets of
wounded and unwounded eyes of each genotype.
Transmission Electron Microscopy (TEM) Analysis
TEM was performed as described previously [23]. For
measurement of collagen diameter, at least ten randomly-selected
fields of WT or SPARC2/2 conjunctiva (magnification,
56,0006) were photographed. The fibril diameters were measured
in conjunction with the Image J software.
Statistical Analysis
Data are expressed as mean 6 standard deviation (SD) where
appropriate. The significance of differences among groups was
determined by the two-tailed Student’s t-test with the Microsoft
Excel 5.0 software, with significance at a P,0.05.
Results
SPARC Deficiency Diminishes the Production of ECM
Proteins but Not Myofibroblast Differentiation Induced
by TGF-b2
To assess the effects of SPARC depletion on the conjunctival
wound healing response, we performed a series of experiments in
vitro with conjunctival fibroblasts derived from either WT or
SPARC2/2 murine eyes. Excess production and deposition of
ECM proteins induced by TGF-b are known to play an important
role in the development of fibrosis [24]. To evaluate the response
of SPARC2/2 conjunctival fibroblasts to TGF-b2, we examined
the expressions of collagen I and fibronectin. The effect of SPARC
depletion on the synthesis of collagen I was striking. First,
SPARC2/2 fibroblasts appeared intrinsically to produce 1.6-fold
lower levels of collagen I in comparison to WT cells (Figure 1A).
Second, collagen I was not enhanced by TGF-b2 in the
SPARC2/2 cells, whereas WT conjunctival fibroblasts exhibited
a 1.3-fold spike in collagen I (Figure 1A). Similarly, TGF-b2
induced a markedly enhanced production of fibronectin by WT
cells (1.5-fold, Figure 1B). In contrast, SPARC2/2 cells showed a
Figure 1. Effect of TGF-b2 on collagen I, fibronectin, and a-SMA
mRNA expression. Cells treated with TGF-b2 for 72 h were measured
for collagen I, fibronectin or a-SMA mRNA abundance by real-time
quantitative PCR. (A) In the presence of TGF-b2, collagen I mRNA was
increased in WT (*, P=1.0610
25) but not in SPARC2/2 conjunctival
fibroblasts. The unstimulated level of collagen I mRNA in SPARC2/2
cells was significantly lower than that in WT cells (P=4.3610
29). (B) In
the presence of TGF-b2, fibronectin mRNA was enhanced in WT (*,
P=0.002) but not in SPARC2/2 conjunctival fibroblasts. (C) In the
presence of TGF-b2, a-SMA mRNA was increased in both WT and
SPARC2/2 conjunctival fibroblasts (*, P,0.001). The b-actin transcript
was used for normalization. Data are shown as fold induction compared
with unstimulated WT cells. Data shown are representative of three
independent experiments.
doi:10.1371/journal.pone.0009415.g001
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TGF-b2 (Figure 1B). Altogether these data imply that SPARC
deficiency may alleviate the fibrotic phenotype by reduction of the
ECM components collagen I and fibronectin in the presence of
TGF-b2. Moreover, the reduced levels of endogenous collagen I
indicate that the healing response in the conjunctiva might be
altered in SPARC2/2 mice.
TGF-b is also an important inducer of epithelial-mesenchymal
transition (EMT) in vivo and in vitro [25]. It is considered to be the
major factor for the differentiation of fibroblasts into myofibro-
blasts, in part due to its augmentation of the expression of the
EMT marker a-SMA in fibroblasts. To determine whether
depletion of SPARC affects TGF-b2-induced myofibroblast
differentiation in conjunctival fibroblasts, we measured the
expression of a-SMA in SPARC2/2 and WT cells. Induction
of a-SMA mRNA was observed in the presence of TGF-b2 in both
WT and SPARC2/2 fibroblasts (Figure 1C). The similar
response observed between SPARC2/2 and WT cells indicates
that SPARC is not involved in the regulation of TGF-b2-induced
myofibroblast differentiation of conjunctival fibroblasts.
The Absence of SPARC Is Associated with Reduced
Fibroblast Contractility Concomitant with Reduced MMP-
2 Activity
Contraction of newly-formed granulation tissue by fibroblasts to
bring together the wound edges is an essential process in wound
healing [26]. To assess the effect of SPARC deficiency in wound
contraction in vitro, we utilized the well-established three-
dimensional collagen gel contraction model [21,27–29]. In the
free-floating gel model, there is no resistance to the contractile
force exerted by the cells, and actin stress fibers are minimally
involved in the process [30]. In this study, WT or SPARC2/2
fibroblasts were cultured in 3D collagen matrices and gel area was
measured over 5 days. Contraction, represented by gel area
expressed as a percentage of the initial area, was rapid within the
first 24 h. Subsequent to the initial 24 h, the rate of contraction
decreased and notably, SPARC2/2 cells contracted less rapidly
than WT cells (Figure 2A). As shown in Table 1, the rate of gel
contraction between day 3 and day 5 was 2.7-fold slower for
SPARC2/2 cells in comparison to WT cells.
Matrix metalloproteinases (MMPs) are required for fibroblast-
mediated collagen matrix contraction and ECM remodelling [31].
We therefore examined the activity of MMPs secreted by the mouse
fibroblasts seeded in the contracted collagen matrices. Conditioned
media were collected from the contracted matrices on day 5 and
evaluated by gelatin zymography. Bands of proteolytic activity
corresponding to MMP-9 and to pro- and active MMP-2 were
Figure 2. Reduction in the rate of collagen gel contraction by
SPARC2/2 fibroblasts is associated with a reduction in the
expression of MT1-MMP and activity of MMP-2. (A) SPARC2/2
conjunctival fibroblasts contracted free-floating collagen gels to a lesser
extent, in comparison to that of WT cells. WT or SPARC2/2 fibroblasts
were seeded in triplicate in collagen solutions which were allowed to
polymerize. Gels were immediately detached and gel contraction was
digitally photodocumented on day-1, -3 and 25. Gel contraction was
measured as a reduction of gel surface area, expressed as a % of the
initial gel size measured immediately after detachment. Values are the
means of triplicates; bars indicate SD. The data shown are represen-
tative of three independent experiments. The rates of contraction from
day-3 to day-5 are shown in Table 1. (B) MMP-2 activity was reduced in
medium conditioned by SPARC2/2 fibroblasts seeded in collagen gels.
Left panel, MMP-2 activity in medium conditioned by WT or SPARC2/2
fibroblasts seeded in collagen gels for 5 days was analysed by gelatin
zymography. Proteolytic activities corresponding to the molecular
weights of MMP-9 (92 kDa) and pro- and active MMP-2 (72 and 66 kDa
respectively) are indicated by arrowheads. Right panel, densitometric
analysis of total MMP-2 (sum of pro- and active MMP-2) showed that
the total MMP-2 secreted by SPARC2/2 cells was significantly lower
that of WT cells (P=2.8610
25). Values shown are the mean of three
independent experiments; bars indicate SD. (C) MT1-MMP expression
was reduced in SPARC2/2 fibroblasts. Left panel, WT or SPARC/2
fibroblasts seeded in collagen gels for 5 days were lysed, and 40 mgo f
each protein preparation was subjected to immunoblotting with
antibodies specific for MT1-MMP and GAPDH (control). Right panel,
upon normalization with the housekeeping protein GAPDH, densitom-
etry analysis revealed that SPARC2/2 fibroblasts produced significantly
less MT1-MMP protein compared to WT cells (P=0.04). Values shown
are the mean of three independent experiments and a representative
Western blot is shown; bars indicate SD. (D) The reduced rate of
collagen gel contraction observed in SPARC2/2 cells did not involve a-
SMA. WT or SPARC/2 fibroblasts seeded in collagen gels for 5 days
were lysed, and the corresponding SPARC or a-SMA mRNAs were
quantified by real-time quantitative PCR. The data confirmed that
SPARC expression was sustainably reduced at day-5 in the collagen gels.
Values shown are the means of triplicates; bars indicate SD.
doi:10.1371/journal.pone.0009415.g002
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conditioned media from the SPARC2/2 cells was reduced in
comparison to that from the WT cells, in stark contrast to the level
of MMP-9 activity, which was not obviously different between the
two cell types (Figure 2B, left panel). Hence, the inhibitory effect of
SPARC depletion on MMP activity appears to be selective for
MMP-2. Moreover, measurement of the total MMP-2 indicated
that SPARC2/2 cells secreted 2.1-fold less of total MMP-2
compared to WT cells (Figure 2B, right panel). Since MMP-2
activation is dependent on the formation of a trimolecular complex
consisting of MT1-MMP, pro-MMP-2, and TIMP-2 [32], we
proceeded to determine whether the reduction in MMP-2 activity
was due to an alteration in the expression of MT1-MMP. Indeed,
immunoblots of the celllysates derived from the contractedmatrices
after 5 days showed a clear reduction in MT1-MMP in the
SPARC2/2 relative to the WT cells (Figure 2C, left panel).
Densitometric analysis corrected for the housekeeping gene
GAPDH confirmed a 5.5-fold reduction in MT1-MMP levels in
SPARC2/2 fibroblasts (Figure 2C, right panel). We further
verified thatthefree-floating matricescontracted independent ofthe
involvementofactin stressfibers bydeterminingtheexpression ofa-
SMA in the cells derived from the 5-day old gels. As shown in
Figure 2D, SPARC2/2 cells expressed equivalent amounts of a-
SMA mRNA as WT cells cultured in the collagen gels. Hence, the
slower rate of day 3 to day 5 collagen gel contraction conferred by
the SPARC2/2 cells is potentially due to a reduction in MT1-
MMP and MMP-2 activities.
SPARC Deficiency Prolongs Bleb Survival in a Murine
Model of Glaucoma Filtration Surgery
To investigate the effect of inactivation of the Sparc gene on
functional wound maintenance, we created a murine model of
glaucoma filtration surgery. In brief, the conjunctiva was surgically
dissected toexposetheunderlyingsclera,afterwhichanincisionwas
made through the sclera into the anterior chamber of the eye to
create a fistula (Figure 3A). This surgically-created channel
facilitates the outflow of aqueous humor from the anterior chamber
into the subconjunctival space, and thereby effectively reduces the
IOP. Filtration of fluid is obvious as an elevated conjunctival bleb,
which is readily observed by slit lamp microscopy (Figure 3B). The
blebs on day 2 post-surgery were visible as raised and swollen areas
of the conjunctiva in WT and SPARC2/2 eyes (Figure 3B, iii and
iv). However, by day-14 post-surgery, all the WT wounded eyes
appeared to have lost the blebs as evidenced by the flattened
conjunctiva (Figure 3B, v), whereas the majority of SPARC2/2
wounded eyes retained the blebs (Figure 3B, vi).
Further analysis by anterior segment optical coherence
tomography (AS-OCT) was performed to evaluate bleb size and
bleb survival. OCT measurements on day-2, -7, -10 and 214 post-
surgery confirmed the slit lamp observations (Figure 4A). The bleb
in a representative WT wounded eye can be observed to reduce
progressively in size until its complete disappearance by day-14
(Figure 4A). In contrast, the bleb in a representative SPARC2/2
wounded eye remained visible on each of the indicated days for at
least 14 days (Figure 4A). In fact, the measured bleb sizes of the
individual SPARC2/2 mice (n=8) were generally larger than
those of the WT mice (n=8) on all the days measurements were
taken (Figure 4B). Bleb size is a representation of filtering efficiency
of the functioning wound. Hence, the SPARC2/2 blebs
appeared to be substantially more efficient in the facilitation of
aqueous filtration than WT blebs: 37.5% (3/8) on day-4, 50% (4/
8) on day-7, 50% (4/8) on day-10 and 37.5% (3/8) on day-14 of
the SPARC2/2 blebs were larger than their corresponding day-2
blebs, i.e. .100% of the size on day 2. This result is in contrast to
25% (2/8) of the WT blebs on day-4 appearing larger than their
corresponding day-2 blebs. Moreover, the largest SPARC2/2
bleb size measured was more than 2-fold the size of its day-2 bleb
size (230%) in comparison to the largest WT bleb measured,
which was only marginally larger in size compared to its size on
day-2 (106%) (day 4, Figure 4B).
Although the bleb sizes generally diminished progressively with
wound age regardless of the genotype, the decline was notably
steeper for the WT eyes. The differenceinbleb sizebetween the two
genotypes was most prominent on day-14 when the mean bleb size
of wounded SPARC2/2 eyes was 82% of the correspondingday-2
blebs, compared to 20% in wounded WT eyes (Figure 4B). Bleb
sizes, even when expressed as percentages of the corresponding day-
2 sizes, can vary significantly between individual eyes. Difficulties in
regulation of the wound size during the surgical process, as well as
variations in the wound response among individual mice, are likely
to contribute to this spread. Judging bleb survival based on bleb size
per se in this model might therefore not be practical or accurate.
Hence, to allow for quantification of bleb survival, we deemed a
bleb size that measured $50% of the size at day-2 as a functioning
bleb, that is, positive for bleb survival whereas a bleb size of ,50%
was considered a failure and non-survival. Using this criterion, we
determinedthatbleb survivalwasnilinWTeyes(0/8)and 87.5%in
SPARC2/2 eyes (7/8) on day-14 post-wounding (Figure 4C). In
summary, both slit lamp and OCT measurements indicated that
SPARC2/2 mice maintained better bleb survival and majority
retained at least 50% of the initial bleb size relative to responses
observed in WT eyes 14 days post-surgery.
SPARC2/2 Conjunctiva Exhibits a Diffuse Connective
Tissue Layer and Responds to Wounding in a Manner
Distinct from WT Tissue
The mouse conjunctiva is composed of an epithelial covering of
two to four layers of keratinocytes resting on a loose collagenous
Table 1. Comparison of the rate of collagen gel contraction from day-3 to -5 between WT and SPARC2/2 mouse conjunctival
fibroblasts.
Mean % of initial
gel size on day 3
Mean % of initial
gel size on day 5
Mean rate of contraction between
day 3 and day 5 (% of initial gel size/day) Fold slower in rate
WT 35.8460.16 25.5361.70 25.1660.77
* 1
SPARC2/2 32.8360.27 28.9960.65 21.9260.19
* 2.69
Values represent the mean % of initial gel sizes 6 SD of 3 independent experiments, each performed in triplicate. The rate of contraction between day 3 and day 5 is
evaluated as the difference in % of initial gel size between day 5 and day 3 over 2 days. The mean rate of contraction is the average of the rates of contraction of 3
independent experiments. The fold slower in rate is calculated based on mean rate of contraction from day 3 to day 5 of WT over SPARC2/2 fibroblasts.
*P=0.01.
doi:10.1371/journal.pone.0009415.t001
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PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9415Figure 3. Creation of a filtering bleb in a mouse model of human glaucoma filtration surgery. (A) Schematic diagram of the surgical
process involved in the creation of a functioning wound in the mouse conjunctiva. The conjunctiva was first surgically dissected to expose the
underlying sclera (i) which was then cannulated with a 30-gauge needle through the sclera into the anterior chamber of the eye (ii) to allow aqueous
humor to escape (small red arrows, iii). Finally, the conjunctiva was closed by suturing over the newly-created fistula (iv). The conjunctiva overlying
the wound site can be observed as a filtering bleb (iv). (B) Slit lamp examination of wound sites revealed the bleb in SPARC2/2 conjunctiva 14 days
post-surgery. The conjunctiva in the unwounded eye is flat and smooth (i, ii). On day-2 post-wounding, the wound site close to the suture
(arrowhead) assumed the appearance of a bleb (demarcated by arrows), indicative of functionality due to the collection of aqueous fluid in the
conjunctiva (iii, iv). On day-14 post-surgery, the WT bleb belonging to the same eye as (iii) has completely flattened down to resemble superficially
the unwounded conjunctiva (v), whereas the SPARC2/2 bleb belonging to the same eye in (iv) remained visibly elevated (vi, outlined by dotted line
and demarcated by arrows).
doi:10.1371/journal.pone.0009415.g003
SPARC Alters Surgical Fibrosis
PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9415Figure 4. Bleb survival is prolonged in the absence of SPARC. (A) Anterior segment optical coherence tomography imaging of the mouse
conjunctiva confirmed bleb survival in the SPARC2/2 conjunctiva. The unwounded and wounded eyes on day-2, -7, -10 and 214 were examined.
The location of the bleb is indicated by the white box. The bleb was seen to diminish progressively in the WT wounded eye until its virtual
disappearance on day-14, whereas the bleb remained visibly present in the SPARC2/2 eye. Images shown belong to the same WT or SPARC2/2 eye
at each of the days examined and are representative of eight eyes of each genotype. C, cornea. (B) Bleb sizes of SPARC2/2 mice were larger than
those of WT animals. Each bleb at the indicated day post-wounding was measured centrally in at least five OCT imaging fields, and the mean size was
expressed as a percentage of the initial size on day-2 post-surgery. Each symbol represents a single eye (¤, WT, n=8; %, SPARC2/2, n=8). The
horizontal bars and numbers indicate the mean % bleb sizes. (C) Kaplan-Meier curve showing that targeted inactivation of SPARC resulted in
increased bleb survival in comparison to that observed in WT eyes. Individual eyes were scored as positive for bleb survival when the bleb size was
$50% of the initial day-2 bleb as shown in (B). Bleb failure in WT eyes progressed rapidly from 25% (2/8) on day-7 to 87.5% (7/8) and 100% (8/8) on
days-10 and -14 post-surgery, respectively, whereas SPARC2/2 blebs experienced only 12.5% failure (1/8) on day-14 post-surgery.
doi:10.1371/journal.pone.0009415.g004
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visualize the conjunctiva in vivo, we examined the day-14 eyes by
confocal microscopy. As shown in Figure 5A, the normal WT
conjunctiva is organized into a distinct outermost epithelial layer
followed by a spongy subconjunctival space (stroma) juxtaposed
posteriorly to the sclera. The SPARC2/2 subconjunctival space
appeared less optically dense in comparison to the WT
conjunctiva (Figure 5, A and B). At day-14 post-wounding, the
WT conjunctival space had collapsed into a compact and optically
dense matrix lacking filtering space for aqueous outflow
(Figure 5C). In contrast, the wounded SPARC2/2 subconjunc-
tival space had expanded at the site of the surgery and was
interlaced with optically diffuse matrix material (Figure 5D). The
loosely-organized matrix in the latter would be advantageous for
the filtration of aqueous fluid through the fistula and percolation
through the stromal network.
SPARC2/2 Wounded Conjunctiva Exhibits Deficient
Collagen Deposition and Scar Formation
We next investigated the physio-anatomical differences under-
lying the wound response between WT and SPARC2/2 eyes.
The eyes were cryosectioned on day-14 post-surgery and then
subjected to histopathological analyses. The SPARC2/2 con-
junctival epithelium (Figure 6B, iii) was conspicuously thinner than
that in the WT eye (Figure 6B, i). In agreement with data
presented in Figure 5, the wounded day-14 WT conjunctiva was
characterized by thick strands of fibrous material in the
subconjunctival space (Figure 6B, ii). In contrast, the SPARC2/
2 bleb appeared to be vacuous and punctuated with thin, wispy
strands of matrix material (Figure 6B, iv). These observations
indicate that collagen deposition might be altered in the
SPARC2/2 wounds.
To ascertain that collagen deposition in the SPARC2/2 versus
WT conjunctiva is different, sirus red polarization microscopy was
performed. We observed that the thinner conjunctiva in the
SPARC2/2 mouse was associated with a corresponding thinner
collagen layer (Figure 6D, iii), whilst the thicker WT conjunctiva
contained densely staining collagen fibers (Figure 6D, i). At the 14
day-old wound site, the WT conjunctiva appeared to be densely
compacted with thick, well-aligned collagen fibers resembling a
scar (Figure 6D, ii). This arrangement contrasted distinctly with
the mechanically efficient basketweave meshwork of collagen in
normal conjunctiva (Figure 6D, i). On the other hand, the day-14
bleb in the SPARC2/2 eyes contained thin, loosely assembled
collagen fibers in an expanded non-collagenous subconjunctival
space (Figure 6D, iv). Ultrastructural analysis confirmed that the
unoperated WT conjunctiva consisted of tightly-packed collagen
fibrils (Figure 6E, i) that accumulated with the absence of
conspicuous gaps between fibers after surgical wounding
(Figure 6E, ii). In contrast, the unwounded SPARC2/2
conjunctiva featured loosely-organized fibrils (Figure 6E, iii) that
were interspersed with areas of loose connective tissue in the bleb
(Figure 6E, iv). Measurement of the collagen fibrils indicated that
the WT conjunctiva contained thicker collagen fibrils (Figure 6E, i,
inset), with a mean fibril diameter of 122.72629.33 nm, in
comparison to SPARC2/2 conjunctiva, which contained two-
fold thinner collagen fibrils (Figure 6E, iii, inset) with a mean
diameter of 59.5069.34 nm (Figure 6F). Thus, it appears that the
prolonged bleb survival in the SPARC2/2 eyes is related, at least
in part, to the deposition of thinner, fewer, and more loosely-
Figure 5. Differential organization of the SPARC2/2 versus WT subconjunctival tissue matrix is associated with a distinct
wounding response. In vivo confocal imaging of the unoperated WT (A) and SPARC2/2 (B) conjunctiva revealed an optical difference in the
composition and organization of the subconjunctival matrix. On day-14 post-surgery, the WT subconjunctival matrix appeared optically dense and
filled with a tightly packed fibrous material (C), whereas the SPARC2/2 matrix was expanded and optically diffuse, with a loosely-organized fibrous
network (D). Images shown are representative of 3 eyes of each genotype. CE, conjunctival epithelium; *, subconjunctival space; S, sclera.
doi:10.1371/journal.pone.0009415.g005
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PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9415Figure 6. Collagen deposition is altered in the SPARC2/2 conjunctiva. (A) Hematoxylin and eosin staining revealed a flattened conjunctiva at
the 14 day-old WT wound site (ii, arrowheads), whereas the SPARC2/2 wound site was observed as a spongy protuberance in the conjunctiva (iv,
arrowheads). (B) Higher magnification of insets (boxed areas in A) illustrate differing thickness in the SPARC2/2 (iii and iv) versus WT (i and ii)
conjunctival epithelium, independent of wounding. (C) Picrosirius red-stained sections of the same eyes at low magnification and visualized by
brightfield microscopy. (D) Higher magnification of insets (boxed areas in C) and polarization microscopy revealed a meshwork organization of collagen
fibers in unoperated WT conjunctiva (i) compared to the well-aligned and tightly packed fibers in WT wound (ii), as well as a delicate meshwork in both
unoperated SPARC2/2 conjunctiva (iii) and operated SPARC2/2 bleb (iv). (E) Transmission electron microscopy confirmed a tightly-packed matrix in
the WT conjunctival wound (ii), in contrast to the presence of areas of loosely-organized matrix with open spaces in the SPARC2/2 wound (*, iv).
Ultrastructural analyses also illustrate the intrinsic deposition of smaller collagen fibrils in the unoperated SPARC2/2 eye (iii, inset) compared to WT (i,
inset). (F) Graphical representation of the mean diameter of collagen fibrils(6 SD) from about 10 fields of view of unoperated WT (filled bar, n=400) and
SPARC2/2 conjunctiva (open bar, n=405). *, P=5.1 610
2159. Bars: (A to D) 100 mm; (E) 1 mm; (E, insets) 200 nm.
doi:10.1371/journal.pone.0009415.g006
SPARC Alters Surgical Fibrosis
PLoS ONE | www.plosone.org 9 February 2010 | Volume 5 | Issue 2 | e9415organized collagen fibrils. Conversely, the apparently flattened
wounds in the WT eyes that consisted of dense, parallel bundles of
collagen fibrils is reminiscent of scar formation and is likely to be
the cause of fistula obstruction with impediment of aqueous
outflow leading to bleb failure.
Expression of ECM Components Is Generally Suppressed
in SPARC2/2 Wounds
To identify ECM components in the wounds, we performed
immunofluorescence on normal and wounded mouse conjunctiva.
In agreement with previous observations that production of
SPARC is enhanced at sites of injury, we detected substantial
levels of this matricellular protein in the wounded WT conjunctiva
(Figure 7B), in contrast to the relatively low level in normal
conjunctiva (Figure 7A). The wounded WT conjunctiva exhibited
enhanced staining for collagen I (Figure 7F) in comparison to its
unoperated counterpart (Figure 7E). Notably, the collagen I
immunoreactivity was substantially diminished in the SPARC2/
2 eyes (Figure 7G) with no apparent increase after wounding
(Figure 7H). Staining for fibronectin was also increased after
wounding of the WT conjunctiva (Figure 7J), in comparison to the
operated conjunctiva in which it was barely detectable (Figure 7I).
In the SPARC2/2 conjunctiva, wounding resulted in an
observable increase in fibronectin deposition (Figure 7L) relative
to its unwounded counterpart (Figure 7K). Finally, MMP-2
appeared to be markedly enhanced in WT conjunctiva
after wounding (Figure 7N), whereas its levels in the injured
SPARC2/2 conjunctiva were minimal (Figure 7P).
Discussion
This study reports a novel therapeutic application of SPARC
depletion in the inhibition of conjunctival scarring and the
concomitant preservation of bleb survival. Furthermore, we
describe here for the first time a murine model of experimental
glaucoma filtration surgery. This model illustrates that SPARC
plays a pivotal role in ECM organization that is crucial to the
maintenance and function of surgically-induced fistula. Beyond its
potential application for the evaluation of new therapeutics for
glaucoma filtration surgery, this model could be important for the
evaluation of post-operative wound healing, with two advantages:
(i) the eye is accessible to experimental surgery or application of
therapeutics, and (ii), the post-surgical outcome can be easily
observed and readily quantified by a variety of available, well-
established, and independent imaging techniques, all of which are
currently used in the clinical setting such that data generated in vivo
can be directly compared with those in humans.
Our model has validated previous concepts of wound closure
and supports the hypothesis that the primary mechanism of wound
closure occurs via connective tissue matrix deposition, that is, by
newly-synthesized collagen and other ECM and matricellular
proteins [33]. Moreover, the surgical effect of the model in WT
eyes reflected the predicted post-surgical outcome of glaucoma
filtration surgery in the absence of anti-proliferative agents.
Indeed, bleb failure from wound obstruction in glaucoma filtration
surgery has been attributed mainly to the accumulation of collagen
[34], an effect that is demonstrated in our model.
We have shown in the current study that bleb failure on WT
eyes occurred most likely as a result of aqueous outflow obstruction
from excessive deposition and organization of ECM in the
subconjunctival space. Moreover, the organization of the collagen
I fibrils appeared to be mechanically inefficient and likely to
contribute further to bleb failure. Hence, our findings support the
notion that bleb failure in the WT mice is a result of a massive
induction and disorganized deposition of collagenous ECM.
In contrast, the SPARC2/2 wound which appeared ‘‘open’’
and filtering, was associated with a reduction in collagen I fibers
that were assembled as a loose stromal network in the
subconjunctival space. The smaller collagen fibril diameters in
the SPARC2/2 conjunctiva are also likely to contribute to the
‘‘open’’ wound phenotype. This notion is supported by previous
observations in SPARC2/2 skin, in which collagen fibril
Figure 7. SPARC2/2 conjunctival wounds exhibit reduced levels of ECM proteins. Immunofluorescence analyses of normal conjunctiva
and wound sites in the WT and SPARC2/2 eye revealed that wounding in the WT conjunctiva was associated with increased production of SPARC
(B), collagen I (F), fibronectin (J) and MMP-2 (N) in comparison to normal WT conjunctiva (A, E, I, M). The SPARC2/2 conjunctiva exhibited no SPARC
expression (C, D) and apparently low levels of collagen I (G), and MMP-2 (O) which were not enhanced upon surgical wounding (H, P). There was an
apparent increase in fibronectin in the SPARC2/2 bleb (L) relative to that in the unoperated SPARC2/2 conjunctiva (K). Mouse anti-SPARC and anti-
fibronectin antibodies were visualized with anti-mouse secondary antibody conjugated to AlexaFluro-488 (green); rabbit anti-collagen and anti-MMP-
2 antibodies were visualized with anti-rabbit secondary antibody conjugated to AlexaFluro-594 (red). Bar, 100 mm.
doi:10.1371/journal.pone.0009415.g007
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that likely contributes to the delayed cutaneous healing observed
in another study [36]. Furthermore, altered collagen assembly in
SPARC2/2 wounds has been correlated with less efficient
wound healing in myocardial infarcts, a condition leading to
increased incidences of cardiac rupture and failure [37]. Our
complementary experiments in vitro verified that, in the absence of
SPARC, TGF-b2-induced collagen I mRNA was attenuated.
Therefore, bleb survival in the SPARC2/2 eye can be attributed,
at least in part, to diminished collagen I deposition due to a lack of
response to TGF-b2 upon wounding.
Several mechanisms have been put forward to explain the
reduced expression of collagen I in SPARC2/2 cells. One idea is
the requirement for SPARC in the post-translational processing of
collagen, where it acts as a molecular chaperone to ensure its
stability [38]. Indeed, SPARC has been shown to regulate
procollagen I processing and collagen fibrillogenesis in skin
fibroblasts [35]. This activity could account for collagen stability
at the post-translational level and perhaps even for the altered
assembly of collagen fibril units in the absence of SPARC. Given
our finding that collagen I mRNA levels were perturbed in the
SPARC2/2 cells, we propose that other mechanism(s) must also
be invoked. One possibility is the function of SPARC in the
regulation of signaling pathways affecting collagen I expression.
Both platelet-derived growth factor and fibroblast growth factor-2
modulate collagen I expression [39,40], and SPARC is known to
affect the activities of these growth factors [10].
The canonical TGF-b signaling pathway involving Smads [41] is
known to be involved in the regulation of collagen and fibronectin
mRNA transcription [39,42]. Our observation that SPARC2/2
conjunctival fibroblasts failed to increase collagen I expression upon
the addition of exogenous TGF-b2 in vitro indicates a central
involvement of SPARC in the TGF-b signaling pathway. Indeed,
expressionofTGF-b and SPARChasbeenshowntoberegulatedin
a reciprocal fashion [43]. The sustained ability of SPARC2/2 to
respond to TGF-b2 by inducing a-SMA mRNA in vitro, points to a
role for SPARC in selectively regulating the intracellular canonical
TGF-b-induced signaling pathway(s) involved in collagen I and
fibronectin expressions in conjunctival fibroblasts.
SPARC is a crucial player in collagen regulation since we found
the inhibitory effect of SPARC deficiency on collagen expression
was consistently observed in both in vitro and in vivo experiments.
This was not so for fibronectin, where we observed an
enhancement of expression in the SPARC2/2 wounds in vivo,
in apparent contradiction to the in vitro failure to upregulate its
expression in response to TGF-b2. This suggests that the in vivo
upregulation of fibronectin is a wound response unrelated to TGF-
b2 induction. Our observation may also be a reflection of the
diverse regulatory pathways involved in regulating fibronectin
deposition where SPARC may be dispensible. For instance,
fibronectin may be deposited in the wound ECM from the
systemic plasma pool [44]. Nevertheless, the evidence suggests that
inhibition of collagen I deposition in response to conjunctival
injury is sufficient to delay or inhibit wound closure.
That SPARC has been shown to regulate MMP activity [45]
supports our data showing that the lack of SPARC is associated
with a reduction in MMP-2 activity, concomitant with a decrease
in MT1-MMP expression in conjunctival SPARC2/2 fibroblasts
seeded in the 3D collagen gels. MMPs are known to play critical
roles in mediating ECM contraction via its degradation to
facilitate the migration of cells and remodel new ECM
[32,46,47]. Therefore, less MMP activity in SPARC2/2
fibroblasts is likely to be a primary cause for the slower rate of
collagen gel contraction that we observed in this study. Since
contraction enhances wound closure, a slower rate of contraction
in the absence of SPARC would in turn delay closure. Moreover,
MMP-2 is known to regulate cell migration and angiogenesis, both
of which contribute to the development of fibrosis [48]. Hence,
reduced MMP-2 expression and activity are likely to help preserve
SPARC2/2 wound functionality by a delay in wound contrac-
tion and inhibition of fibrotic wound healing.
In conclusion, this is the first study demonstrating that SPARC
plays a pivotal role in post-operative subconjunctival scarring and
that its loss can preserve the presence of a filtering bleb. Inhibition
of SPARC expression should be considered as a therapeutic tool to
improve glaucoma filtration surgical outcome. Our future work
involves employing the gene silencing technology through the
application of SPARC-targeting small interfering RNA (siRNA) to
reduce SPARC expression in the surgical wound. We believe that
this method will be more effective than using SPARC neutralizing
antibodies since our data suggests that the mode of action of
SPARC is intracellular rather than extracellular, at least where
interruption with TGF-b2-mediated induction of ECM produc-
tion is concerned. SPARC is probably not involved in regulating
the availability of secreted TGF-b2 to its receptors as was
suggested previously for TGF-b1 [43] since that would result in
a curtailment of all TGF-b2 signaling in SPARC2/2 cells. The
selective inhibition of TGF-b2-induced expression of collagen I
and fibronectin but not a-SMA implies that SPARC affects TGF-
b2 signaling intracellularly and that diverging pathways are
involved in the regulation of collagen I and fibronectin expressions
versus a-SMA expression. Hence, future work involves the
development of effective SPARC siRNA(s) as well as efficient
delivery systems for it so as to improve the survival of the filtering
bleb without the need for anti-proliferatives in glaucoma filtration
surgery.
Supporting Information
Table S1 Primers used with real-time PCR.
Found at: doi:10.1371/journal.pone.0009415.s001 (0.02 MB
DOC)
Acknowledgments
We thank Sia Wey Yeo (Singapore Eye Research Institute) for assistance
with the mouse model. We thank the Department of Pathology, Yong Loo
Lin School of Medicine, National University of Singapore, for help with
the polarization microscopy.
Author Contributions
Conceived and designed the experiments: L-FS TW. Performed the
experiments: L-FS RS VAB WSL RP YMH TW. Analyzed the data: L-FS
TW. Contributed reagents/materials/analysis tools: YMH EM ENV TA
MW EHS TW. Wrote the paper: L-FS TW.
References
1. Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, et al. (2004)
Global data on visual impairment in the year 2002. Bull World Health Organ
82: 844–851.
2. Quigley HA, Broman A (2006) The number of persons with glaucoma
worldwide in 2010 and 2020. Br J Ophthalmol 90: 151–156.
3. The AGIS Investigators (2000) The advanced glaucoma intervention study
(AGIS): 7. The relationship between control of intraocular pressure and visual
field deterioration. Am J Ophthalmol 130: 429–440.
4. Reddick R, Merritt JC, Ross G, Avery A, Peiffer RL (1985) Myofibroblasts in
filtration operations. Ann Ophthalmol 17: 200–203.
SPARC Alters Surgical Fibrosis
PLoS ONE | www.plosone.org 11 February 2010 | Volume 5 | Issue 2 | e94155. The Fluorouracil Filtering Surgery Study Group (1989) Fluorouracil filtering
surgery study one-year follow-up. Am J Ophthalmol 108: 625–635.
6. Kitazawa Y, Kawase K, Matsushita H, Minobe M (1991) Trabeculectomy with
mitomycin. A comparative study with fluorouracil. Arch Ophthalmol 109:
1693–1698.
7. Skuta GL, Beeson CC, Higginbotham EJ (1992) Intraoperative mitomycin
versus postoperative 5-fluorouracil in high- risk glaucoma filtering surgery.
Ophthalmol 99: 438–444.
8. Higginbotham EJ, Stevens RK, Musch DC (1996) Bleb-related endophthalmitis
after trabeculectomy with mitomycin C. Ophthalmol 103: 650–656.
9. Greenfield DS, Suner IJ, Miller MP (1996) Endophthalmitis after filtering
surgery with mitomycin. Arch Ophthalmol 114: 943–949.
10. Brekken RA, Sage EH (2001) SPARC, a matricellular protein: at the crossroads
of cell-matrix communication. Matrix Biol 19: 816–827.
11. Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modulators of
cell function. Curr Opin Cell Biol 14: 608–616.
12. Zhou XD, Tan FK, Reveille JD, Wallis D, Milewicz DM, et al. (2002)
Association of novel polymorphisms with the expression of SPARC in normal
fibroblasts and with susceptibility to scleroderma. Arthritis Rheum 46:
2990–2999.
13. Zhou X, Tan FK, Guo X, Arnett FC (2006) Attenuation of collagen production
with small interfering RNA of SPARC in cultured fibroblasts from the skin of
patients with scleroderma. Arthritis Rheum 54: 2626–2631.
14. Kuhn C, Mason RJ (1995) Immunolocalization of SPARC, tenascin, and
thrombospondin in pulmonary fibrosis. Am J Pathol 147: 1759–1769.
15. Pichler RH, Hugo C, Shankland SJ, Reed MJ, Bassuk JA, et al. (1996) SPARC is
expressed in renal interstitial fibrosis and in renal vascular injury. Kidney Int 50:
1978–1989.
16. Kanauchi M, Nishioka M, Dohi K (2000) Secreted protein acidic and rich in
cysteine (SPARC) in patients with diabetic nephropathy and tubulointerstitial
injury. Diabetologia 43: 1076–1077.
17. Frizell E, Liu SL, Abraham A, Ozaki I, Eghbali M, et al. (1995) Expression of
SPARC in normal and fibrotic livers. Hepatol 21: 847–854.
18. Dhore CR, Cleutjens JPM, Lutgens E, Cleutjens KBJM, Geusens PPM, et al.
(2001) Differential expression of bone matrix regulatory proteins in human
atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21: 1998–2003.
19. Strandjord TP, Madtes DK, Weiss DJ, Sage EH (1999) Collagen accumulation
is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis.
Am J Physiol 277: 628–635.
20. Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, Wight TN, et al.
(2003) SPARC-null mice display abnormalities in the dermis characterized by
decreased collagen fibril diameter and reduced tensile strength. J Invest Dermat
120: 949–955.
21. Arora PD, Narani N, McCulloch CA (1999) The compliance of collagen gels
regulates transforming growth factor-b induction of a-smooth muscle actin in
fibroblasts. Am J Pathol 154: 871–882.
22. Junqueira LC, Bignolas G, Brentani RR (1979) Picrosirius staining plus
polarization microscopy, a specific method for collagen detection in tissue
sections. Histochem J 11: 447–455.
23. Mehta JS, Chua J, Poh R, Beuerman RW, Tan D (2008) Primary graft failure
after descemet-stripping automated endothelial keratoplasty. Cornea 27:
722–726.
24. Branton MH, Kopp JB (1999) TGF-b and fibrosis. Microbes and Infection 1:
1349–1365.
25. Willis BC, Borok Z (2007) TGF-b-induced EMT: mechanisms and implications
for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 293: L525–L534.
26. Clark RAF (1996) Wound repair: overview and general considerations. In:
Clark RAF, ed. The Molecular and Cellular Biology of Wound Repair. New
York: Plenum Press. pp 3–50 .
27. Tamariz E, Grinnell F (2002) Modulation of fibroblast morphology and
adhesion during collagen matrix remodeling. Mol Biol Cell 13: 3915–3929.
28. Grinnell F (1994) Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol
124: 401–404.
29. Grinnell F (2003) Fibroblast biology in three-dimensional collagen matrices.
Trends Cell Biol 13: 264–269.
30. Ehrlich HP, Rajaratnam JB (1990) Cell locomotion forces versus cell contraction
forces for collagen lattice contraction: an in vitro model of wound contraction.
Tiss Cell 22: 407–417.
31. Daniels JT, Schultz GS, Blalock TD, Garrett Q, Grotendorst GR, et al. (2003)
Mediation of transforming growth factor-b1-stimulated matrix contraction by
fibroblasts. Am J Pathol 163: 2043–2052.
32. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, et al. (1994) A matrix
metalloproteinase expressed on the surface of invasive tumor cells. Nature 370:
61–65.
33. Diegelmann R (1997) Cellular and biochemical aspects of normal and abnormal
wound healing: an overview. J Urol 157: 298–302.
34. Esson DW, Neelankantan A, Iyer SA, Blalock TD, Balasubramian L, et al.
(2004) Expression of connective tissue growth factor after glaucoma filtration
surgery in a rabbit model. Invest Ophthalmol Vis Sci 45: 485–491.
35. Rentz TJ, Poobalarahi F, Bornstein P, Sage EH, Bradshaw AD (2007) SPARC
regulates processing of procollagen I and collagen fibrillogenesis in dermal
fibroblasts. J Biol Chem 282: 22062–22071.
36. Basu A, Kligman LH, Samulewicz SJ, Howe CC (2001) Impaired wound
healing in mice deficient in a matricellular protein SPARC (osteonectin, BM-40).
BMC Cell Biol 2: 15.
37. Schellings MWM, Vanhoutte D, Swinnen M, Cleutjens JP, Debets J, et al.
(2008) Absence of SPARC results in increased cardiac rupture and dysfunction
after acute myocardial infarction. J Exp Med 206: 113–123.
38. Martinek N, Shahab J, Sodek J, Ringuette M (2007) Is SPARC an evolutionarily
conserved collagen chaperone? J Dent Res 86: 296–305.
39. Ramirez F, Tanaka S, Bou-Gharios G (2006) Transcriptional regulation of the
human a2(I) collagen gene (COL1A2), an informative model system to study
fibrotic diseases. Matrix Biol 25: 365–372.
40. Ko MK, Kay EP (2005) Regulatory role of FGF-2 on type I collagen expression
during endothelial mesenchymal transformation. Invest Ophthalmol Vis Sci 46:
4495–4503.
41. Shi Y, Massague ´ J (2003) Mechanisms of TGF-ß signaling from cell membrane
to the nucleus. Cell 113: 685–700.
42. Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, et al. (2003) Elucidation
of Smad requirement in transforming growth factor-beta type I receptor-induced
responses. J Biol Chem 278: 3751–3761.
43. Schiemann BJ, Neil JR, Schiemann WP (2003) SPARC inhibits epithelial cell
proliferation in part through stimulation of the transforming growth factor-b–
signaling system. Mol Biol Cell 14: 3977–3988.
44. Moretti FA, Chauhan AK, Iaconcig A, Porro F, Baralle FE, et al. (2007) A major
fraction of fibronectin present in the extracellular matrix of tissues is plasma-
derived. J Biol Chem 282: 28057–28062.
45. McClung HM, Thomas SL, Osenkowski P, Toth M, Menon P, et al. (2007)
SPARC upregulates MT1-MMP expression, MMP-2 activation, and the
secretion and cleavage of Galectin-3 in U87MG glioma cells. Neurosci Lett
419: 172–177.
46. Seltzer JL, Lee A-Y, Akers KT, Sudbeck B, Southon E, et al. (1994) Activation
of 72-kDa type IV collagenase/gelatinase by normal fibroblasts in collagen
lattices is mediated by integrin receptors but is not related to lattice contraction.
Exp Cell Res 213: 365–374.
47. Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A (1998) Remodeling of
collagen matrix by human tumor cells requires activation and cell surface
association of matrix metalloproteinase-2. Cancer Res 58: 3743–3750.
48. Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various
fibroproliferative diseases. J Clin Invest 117: 524–529.
SPARC Alters Surgical Fibrosis
PLoS ONE | www.plosone.org 12 February 2010 | Volume 5 | Issue 2 | e9415